Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ateganosine - MAIA Biotechnology

Next Previous
Drug Profile

Ateganosine - MAIA Biotechnology

Alternative Names: 2'-Deoxythioguanosine; 6-thio-2’-deoxyguanosine - MAIA Biotechnology; 6-thio-dG - MAIA Biotechnology; THIO - MAIA Biotechnology

Latest Information Update: 13 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MAIA Biotechnology
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Purines; Small molecules; Thiones
  • Mechanism of Action Cell death stimulants; DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Small cell lung cancer; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Preclinical Glioma; Liver cancer; Small cell lung cancer

Most Recent Events

  • 08 Jul 2026 Efficacy data from a phase II trial in Non-small cell lung cancer released by MAIA Biotechnology
  • 25 Jun 2026 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) in Georgia (IV) (NCT05208944)
  • 25 Jun 2026 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) in Romania (IV) (NCT05208944)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top